ARS Pharmaceuticals (SPRY) Q2 FY26 earnings call

ARS Pharmaceuticals, under new CEO Don Casale, is implementing a strategic pivot towards disciplined, provider-targeted commercial execution for NEPI, coupled with significant financial optimization to achieve cash flow break-even by late 2027. This shift involves reducing broad direct-to-consumer spending and focusing on high-value prescribers, while also advancing the intranasal epinephrine platform into chronic spontaneous urticaria (CSU) with a Phase 2b trial readout expected in Q1 2027.